| Angela Dawn Pike, DNP, FNP-C, PMHNP-BC | |
|
412 N Vine, Magnolia, AR 71753-2842 | |
| (870) 234-7500 | |
| Not Available |
| Full Name | Angela Dawn Pike |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 3 Years |
| Location | 412 N Vine, Magnolia, Arkansas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790065068 | NPI | - | NPPES |
| P00991383 | Other | MO | RR MEDICARE |
| 1790065068 | Medicaid | MO | |
| 200738960A | Medicaid | KS |
| Facility Name | Location | Facility Type |
|---|---|---|
| Magnolia Hospital | Magnolia, AR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Urgent Care Express Llc | 5294829248 | 11 |
| South Arkansas Regional Health Center | 0941199988 | 13 |
News Archive
Using medication that reduces or blocks the actions of folic acid during the first trimester of pregnancy (weeks 1-12), increases the risk that the growing baby will develop abnormalities. This conclusion was reached by a team of Epidemiologists, Paediatricians, Clinical Pharmacologists, Obstetricians and Gynaecologists who examined birth and abortion data collected in Israel between 1998 and 2007.
During the 5th International Congress of Corneal Cross Linking for Keratoconus in Leipzig, Germany on December 5th, Avedro presented encouraging early clinical results for treating keratoconus, a progressive disease of the cornea of the eye. The procedure, known as Keraflex® KXL, is non-incisional and reshapes the cornea without removing any tissue.
For many patients, the uncertainty and stress that can come with cancer treatment is compounded by what is now known as "financial toxicity," the anxiety and distress that follow health care and medication expenses, often compounded by reduced ability to work.
Magellan Health Services Inc. today reported financial results for the second quarter 2013, as summarized below. For the quarter ended June 30, 2013, the company reported net revenue of $842.7 million, segment profit of $75.0 million, and net income of $31.5 million or $1.15 per diluted common share.
› Verified 7 days ago
| Entity Name | Family Guidance Center For Behavioral Healthcare |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932225141 PECOS PAC ID: 6800707571 Enrollment ID: O20040420000015 |
News Archive
Using medication that reduces or blocks the actions of folic acid during the first trimester of pregnancy (weeks 1-12), increases the risk that the growing baby will develop abnormalities. This conclusion was reached by a team of Epidemiologists, Paediatricians, Clinical Pharmacologists, Obstetricians and Gynaecologists who examined birth and abortion data collected in Israel between 1998 and 2007.
During the 5th International Congress of Corneal Cross Linking for Keratoconus in Leipzig, Germany on December 5th, Avedro presented encouraging early clinical results for treating keratoconus, a progressive disease of the cornea of the eye. The procedure, known as Keraflex® KXL, is non-incisional and reshapes the cornea without removing any tissue.
For many patients, the uncertainty and stress that can come with cancer treatment is compounded by what is now known as "financial toxicity," the anxiety and distress that follow health care and medication expenses, often compounded by reduced ability to work.
Magellan Health Services Inc. today reported financial results for the second quarter 2013, as summarized below. For the quarter ended June 30, 2013, the company reported net revenue of $842.7 million, segment profit of $75.0 million, and net income of $31.5 million or $1.15 per diluted common share.
› Verified 7 days ago
| Entity Name | State Of Missouri |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497709083 PECOS PAC ID: 1456254226 Enrollment ID: O20040609001176 |
News Archive
Using medication that reduces or blocks the actions of folic acid during the first trimester of pregnancy (weeks 1-12), increases the risk that the growing baby will develop abnormalities. This conclusion was reached by a team of Epidemiologists, Paediatricians, Clinical Pharmacologists, Obstetricians and Gynaecologists who examined birth and abortion data collected in Israel between 1998 and 2007.
During the 5th International Congress of Corneal Cross Linking for Keratoconus in Leipzig, Germany on December 5th, Avedro presented encouraging early clinical results for treating keratoconus, a progressive disease of the cornea of the eye. The procedure, known as Keraflex® KXL, is non-incisional and reshapes the cornea without removing any tissue.
For many patients, the uncertainty and stress that can come with cancer treatment is compounded by what is now known as "financial toxicity," the anxiety and distress that follow health care and medication expenses, often compounded by reduced ability to work.
Magellan Health Services Inc. today reported financial results for the second quarter 2013, as summarized below. For the quarter ended June 30, 2013, the company reported net revenue of $842.7 million, segment profit of $75.0 million, and net income of $31.5 million or $1.15 per diluted common share.
› Verified 7 days ago
| Entity Name | Urgent Care Express Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407063209 PECOS PAC ID: 5294829248 Enrollment ID: O20070926000141 |
News Archive
Using medication that reduces or blocks the actions of folic acid during the first trimester of pregnancy (weeks 1-12), increases the risk that the growing baby will develop abnormalities. This conclusion was reached by a team of Epidemiologists, Paediatricians, Clinical Pharmacologists, Obstetricians and Gynaecologists who examined birth and abortion data collected in Israel between 1998 and 2007.
During the 5th International Congress of Corneal Cross Linking for Keratoconus in Leipzig, Germany on December 5th, Avedro presented encouraging early clinical results for treating keratoconus, a progressive disease of the cornea of the eye. The procedure, known as Keraflex® KXL, is non-incisional and reshapes the cornea without removing any tissue.
For many patients, the uncertainty and stress that can come with cancer treatment is compounded by what is now known as "financial toxicity," the anxiety and distress that follow health care and medication expenses, often compounded by reduced ability to work.
Magellan Health Services Inc. today reported financial results for the second quarter 2013, as summarized below. For the quarter ended June 30, 2013, the company reported net revenue of $842.7 million, segment profit of $75.0 million, and net income of $31.5 million or $1.15 per diluted common share.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Angela Dawn Pike, DNP, FNP-C, PMHNP-BC 7401 Whitson Rd, Saint Joseph, MO 64507-7721 Ph: (816) 273-9105 | Angela Dawn Pike, DNP, FNP-C, PMHNP-BC 412 N Vine, Magnolia, AR 71753-2842 Ph: (870) 234-7500 |
News Archive
Using medication that reduces or blocks the actions of folic acid during the first trimester of pregnancy (weeks 1-12), increases the risk that the growing baby will develop abnormalities. This conclusion was reached by a team of Epidemiologists, Paediatricians, Clinical Pharmacologists, Obstetricians and Gynaecologists who examined birth and abortion data collected in Israel between 1998 and 2007.
During the 5th International Congress of Corneal Cross Linking for Keratoconus in Leipzig, Germany on December 5th, Avedro presented encouraging early clinical results for treating keratoconus, a progressive disease of the cornea of the eye. The procedure, known as Keraflex® KXL, is non-incisional and reshapes the cornea without removing any tissue.
For many patients, the uncertainty and stress that can come with cancer treatment is compounded by what is now known as "financial toxicity," the anxiety and distress that follow health care and medication expenses, often compounded by reduced ability to work.
Magellan Health Services Inc. today reported financial results for the second quarter 2013, as summarized below. For the quarter ended June 30, 2013, the company reported net revenue of $842.7 million, segment profit of $75.0 million, and net income of $31.5 million or $1.15 per diluted common share.
› Verified 7 days ago
Andrew Woolfley, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 50 Highway 79 Byp N Ste C, Magnolia, AR 71753 Phone: 870-234-7435 Fax: 870-234-7476 | |
Haley M Quintana, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1617 N Washington # 599, Magnolia, AR 71753 Phone: 870-234-7676 Fax: 870-562-2559 | |
Ginger Ann Mulholland, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1920 South Washington, Magnolia, AR 71753 Phone: 870-949-2807 | |
Tara Almand, APRN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 100 E University, Magnolia, AR 71753 Phone: 870-235-5254 Fax: 870-235-5263 | |
Mrs. Shawntel Marie Price, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1010 N Dudney Rd Ste C, Magnolia, AR 71753 Phone: 870-234-2675 Fax: 870-234-4153 | |
Mrs. Harriet Jean Alexander, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 104 Hospital Dr, Magnolia, AR 71753 Phone: 870-235-3555 Fax: 870-234-2149 | |
Ms. Callie Minter Sexton, FAMILY NURSE PRACTIT Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 207 W Calhoun, Magnolia, AR 71753 Phone: 870-235-3798 |